Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNO-BIOMAP
NCT07288034Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- May 2026
- Primary completion
- Oct 2028
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tremelimumab, durvalumab, adagrasib, bevacizumab in non-small cell lung cancer (NSCLC), sponsored by City of Hope. Started May 2026; status: recruiting.
02
Drugs
tremelimumabdurvalumabadagrasibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07288034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07288034.